PTHrP 1-141 and 1-86 increase in vitro bone formation

Area of Science:

• Bone biology and regeneration
• Endocrinology
• Skeletal anabolic agents

Background:

• Parathyroid hormone-related protein (PTHrP) exhibits bone-building properties, leading to clinical use of its N-terminal fragments.
• Fracture complications and osteoporosis necessitate the development of novel bone-forming agents.

Purpose of the Study:

• To compare the in vitro bone-forming effects of full-length PTHrP (1-141) against its N-terminal fragment (PTHrP 1-86).
• To investigate the anabolic contributions of different PTHrP regions, including the N-terminus, NLS, and C-terminus.

Main Methods:

• MC3T3-E1 pre-osteoblasts were treated with varying concentrations of PTHrP 1-141 or 1-86 for 1 or 24 hours.
• Cells were also treated with peptides after blocking specific regions (N-terminus, NLS, C-terminus) individually and in combination.
• Measurements included area of mineralization, alkaline phosphatase (ALP), and osteocalcin (OCN) levels.

Main Results:

• Both PTHrP 1-141 and 1-86 enhanced mineralization after 24-hour treatments, with PTHrP 1-141 demonstrating greater potency.
• PTHrP 1-141 significantly increased ALP in a concentration-dependent manner after 24-hour exposure.
• Osteocalcin (OCN) levels increased with both peptides after 1- and 24-hour treatments, with longer exposure yielding higher levels.
• Antibody blocking confirmed anabolic roles for the NLS and C-terminus.

Conclusions:

• Both full-length PTHrP 1-141 and the N-terminal fragment PTHrP 1-86 promote in vitro bone formation.
• PTHrP 1-141 exhibits superior efficacy compared to PTHrP 1-86.
• The NLS and C-terminus possess distinct anabolic functions, highlighting the therapeutic potential of the complete PTHrP molecule.